Search PubMed⌕ Search

Biomedical subjects

J J Warsh

Publications and source records attributed to J J Warsh.

At least 37 records · Page 2Linked to original sources
PubMed1997

Reduced [3H]cyclic AMP binding in postmortem brain from subjects with bipolar affective disorder.

Findings of increased Gs alpha levels and forskolin-stimulated adenylyl cyclase activity in selective cerebral cortical postmortem brain regions in bipolar affective disorder (BD) implicate increased cyclic AMP (cAMP)-mediated signaling in this illness. Accumulating evidence suggests that intracellular levels of cAMP modulate the abundance and disposition of the regulatory subunits of cAMP-dependent protein kinase (cAMP-dPK). Thus, in the present study, we tested further whether hyperfunctional Gs alpha-linked cAMP signaling occurs in BD by determining [3H]cAMP binding, a measure of the levels of regulatory subunits of cAMP-dPK, in cytosolic and membrane fractions from discrete brain regions of postmortem BD brain. Specific [3H]cAMP (5 nM) binding was determined in autopsied brain obtained from 10 patients with DSM-III-R diagnoses of BD compared with age- and postmortem delay-matched controls. [3H]cAMP binding was significantly reduced across all brain regions in cytosolic fractions of BD frontal (-22%), temporal (-23%), occipital (-22%) and parietal (-15%) cortex, cerebellum (-36%), and thalamus (-13%) compared with controls, but there were no differences in [3H]cAMP binding in the membrane fractions from these same regions. These results suggest that changes occur in the cAMP-dPK regulatory subunits in BD brain, possibly resulting from increased cAMP signaling. The possibility that antemortem lithium and/or other mood stabilizer treatment may contribute to the above changes, however, cannot be ruled out.

Adult↗
PubMed1997

High intracellular calcium concentrations in transformed lymphoblasts from subjects with bipolar I disorder.

OBJECTIVE: Higher basal concentrations of intracellular calcium Ca2+ in platelets and lymphocytes from subjects with bipolar affective disorder than in unipolar depressed and healthy subjects implicate abnormal intracellular Ca2+ signaling in bipolar disorder. The purpose of this study was to clarify whether these intracellular Ca2+ abnormalities are trait related. METHOD: Basal Ca2+ concentration was measured by using ratiometric fluorescence assay with fura-2 for T lymphocytes and Epstein-Barr-virus-immortalized B lymphoblasts from physically healthy subjects with DSM-IV diagnoses of bipolar mood disorder (bipolar I, N = 28; bipolar II, N = 11) or major depressive disorder (N = 14), mixed psychiatric patients with non-mood disorders (N = 14), and health subjects (N = 20). Phytohemagglutinin-stimulated (10 micrograms/ml) intracellular Ca2+ levels were also determined in T lymphocytes. RESULTS: The basal Ca2+ concentration was significantly higher in the B lymphoblasts from patients with bipolar I disorder, but not bipolar II disorder or major depression, than in healthy subjects or psychiatric patients with nonmood disorders. There was a significant interaction between gender and diagnosis in the effect on basal Ca2+ levels in T lymphocytes. Contrasts of diagnoses within gender revealed significantly higher basal Ca2+ concentrations in T lymphocytes in male bipolar I patients, but not mean with bipolar II disorder or major depression, than in healthy male comparison subjects. Phytohemagglutinin-stimulated Ca2+ concentrations did not differ among groups, but the percent differences from basal Ca2+ levels were lower in bipolar I and depressed patients than in healthy subjects. CONCLUSIONS: These findings support the occurrence of abnormal calcium homeostasis in bipolar disorder and suggest that trait-dependent factors account, at least partly, for the higher basal lymphocyte Ca2+ concentration in bipolar I subjects.

Adult↗
PubMed1996

Genetic variant near cytosolic phospholipase A2 associated with schizophrenia.

Two studies were undertaken to determine a possible genetic basis for alterations in phospholipid metabolism in schizophrenia. Initial results demonstrated an association in 65 schizophrenics compared with a matched normal control population. A follow-up haplotype relative risk study of 44 triads (mother, father, affected offspring), confirmed the results seen in the association study. Results suggest that a genetic variant near the promotor region of the gene for cytosolic phospholipase A2, the rate-limiting enzyme in the synthesis of prostaglandins from arachindonic acid, is associated with schizophrenia.

Female↗
PubMed1996

Lack of effect of antidepressants on mononuclear leukocyte G-protein levels or function in depressed outpatients.

Evidence from studies in animal and cultured cell models suggests that antidepressants (ADs) may enhance postreceptor signalling through the G protein coupled adenylyl cyclase (AC) pathways. To test whether this also occurs in patients receiving AD treatment, G-protein-activated-AC activity and the levels of alpha s and alpha i were measured in mononuclear leukocytes (MNLs) from 12 subjects with major depressive disorder (MDD) at baseline and after a 5 week trial of AD treatment. Although no differences were found in GTP gamma S-and forskolin-stimulated AC activity or the levels of alpha s and alpha i in MDD subjects compared with age- and sex-matched healthy subjects, pretreatment basal AC activity was significantly lower in treatment responders compared with healthy subjects. No significant changes were evident in any of these biochemical measures following 5 weeks of AD treatment in the patient group as a whole or stratified by response. These findings do not support an effect of ADs on the G-protein AC pathway, at least in MNLs. Lower pretreatment basal AC activity in responders suggests some change(s) in post-receptor signalling processes may be associated with an increased likelihood of therapeutic response to ADs.

Adenylyl Cyclases↗
PubMed1996

Brain region-specific and time-dependent decreases of G alpha i2 in amygdala-kindled rats.

Immunoreactivity levels of G protein alpha-subunits, Galphas (45 and 52 kDa), Galphai1, and Galphai2, were determined in plasma membranes prepared from ipsilateral amygdala-pyriform cortex (AM/PC), contralateral AM/PC, dorsal hippocampus (DH), and ventral hippocampus (VH) in amygdala-kindled rats 24 h, 1 month, and 3 months after the last seizure. Relative to sham controls, immunoreactivity levels of Galphai2 were significantly reduced in ipsilateral AM/PC and DH, with maximal decreases observed, respectively, at 24 h (26% form control levels) and 1 month (18% from control levels) postseizure. No significant alterations in the levels of Galphai1 or either of the Galphas isoforms were observed. The reduction in Galphai2 levels was, however, not accompanied by measurable changes in Galphai-mediated inhibition of adenylyl cyclase, as estimated by GppNHp modulation of forskolin-activated adenylyl cyclase activity. The present findings add support to the hypothesis that long-term changes in brain functioning following kindling may involve altered expression and/or function of components of the transmembrane signalling cascade, including G proteins.

Adenylyl Cyclases↗
PubMed1996

Lack of effect of chronic antidepressant treatment on Gs and Gi alpha-subunit protein and mRNA levels in the rat cerebral cortex.

Experimental evidence indicates that chronic antidepressant treatment in rats modifies the central nervous system beta-adrenoceptor signaling pathway at multiple sites including receptor, G-protein, adenylyl cyclase, and protein kinase A. In the present study, we examined the postreceptor effect of antidepressant treatment on the protein and mRNA levels of stimulatory and inhibitory C protein alpha-subunits (G alpha s and G alpha i) and beta-subunits in rats infused continuously with various antidepressants for 21 days. Chronic treatment with tricylic (desipramine and amitriptyline) and monoamine oxidase inhibiting (tranylcypromine) antidepressants did not significantly affect the immunoreactivity levels of G alpha s (both 45- and 52-kDa species), G alpha i1, G alpha i2, G beta 36, and beta 35 in rat cerebral cortex. Similarly, the levels of mRNA encoding these G protein subunits remained unchanged subsequent to these drug treatments. In contrast, cortical beta-adrenoceptor number was significantly decreased by these treatments. These results suggest that the adaptive changes of rat cerebral cortical beta-adrenoceptor-adenylyl cyclase system often seen after chronic antidepressant treatment are not accompanied by changes in the abundance and gene expression of G alpha s, G alpha i, or G beta proteins.

Analysis of Variance↗
PubMed1996

Stimulatory G-protein alpha-subunit mRNA levels are not increased in autopsied cerebral cortex from patients with bipolar disorder.

Increased alpha-subunit (alpha s) levels of both the 45- and 52-kDa isoforms of the stimulatory guanine nucleotide binding protein (G-protein), have been found in postmortem brain and mononuclear leukocytes from patients with bipolar disorder (BD). The pathophysiological mechanism responsible for increased alpha s protein levels is unknown, however, it may involve increased expression of the gene encoding this protein. To assess this possibility, alpha s mRNA levels were determined by RT-PCR in postmortem brain from 10 subjects with an antemortem diagnosis of BD and age- and sex-matched control subjects in whom we had previously reported increased alpha s protein levels. There were no significant differences in alpha s mRNA levels in frontal, temporal, or occipital cortex between BD and control subjects. Cerebral cortex alpha s mRNA levels did not correlate with age or postmortem interval. These findings do not support the notion that higher alpha s levels found in BD postmortem brain are a result of increased gene expression.

Adult↗
PubMed1996

The phosphoinositide signal transduction system is impaired in bipolar affective disorder brain.

The function of the phosphoinositide second messenger system was assessed in occipital, temporal, and frontal cortex obtained postmortem from subjects with bipolar affective disorder and matched controls by measuring the hydrolysis of [3H]phosphatidylinositol ([3H]PI) incubated with membrane preparations and several different stimulatory agents. Phospholipase C activity, measured in the presence of 0.1 mM Ca2+ to stimulate the enzyme, was not different in bipolar and control samples. G proteins coupled to phospholipase C were concentration-dependently activated by guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S) and by NaF. GTP gamma S-stimulated [3H]Pl hydrolysis was markedly lower (50%) at all tested concentrations (0.3-10 microM GTP gamma S) in occipital cortical membranes from bipolar compared with control subjects. Responses to GTP gamma S in temporal and frontal cortical membranes were similar in bipolars and controls, as were responses to NaF in all three regions. Brain lithium concentrations correlated directly with GTP gamma S-stimulated [3H]Pl hydrolysis in bipolar occipital, but not temporal or frontal, cortex. Carbachol, histamine, trans-1-aminocyclopentyl-1,3-dicarboxylic acid, serotonin, and ATP each activated [3H]Pl hydrolysis above that obtained with GTP gamma S alone, and these responses were similar in bipolars and controls except for deficits in the responses to carbachol and serotonin in the occipital cortex, which were equivalent to the deficit detected with GTP gamma S alone. Thus, among the three cortical regions examined there was a selective impairment in G protein-stimulated [3H]Pl hydrolysis in occipital cortical membranes from bipolar compared with control subjects. These results directly demonstrate decreased activity of the phosphoinositide signal transduction system in specific brain regions in bipolar affective disorder.

Adenosine Triphosphate↗
PubMed1995

Developmental expression of G alpha o and G alpha s isoforms in PC12 cells: relationship to neurite outgrowth.

Recent evidence suggests neuronal differentiation is associated with developmentally regulated changes in the expression of certain G-protein subtypes but the relationship of such changes to neuronal differentiation and/or neurite outgrowth is poorly understood. In this study, the appearance of the G-protein alpha o and alpha s subunit isoforms was characterized in NGF-induced differentiating pheochromocytoma (PC)12 cells and correlated with neurite outgrowth, which was assessed with direct morphometric measures at 24-h intervals for a 5-day period and at 24, 48 and 72 h following NGF removal. Significant increases were observed in alpha o1 immunoreactive levels and the ratio of alpha o1/alpha o2 immunoreactivities during NGF exposure but not in the levels of either the long or short isoform of alpha s. The former changes also correlated significantly with neurite length during NGF treatment. Furthermore, no significant changes were observed in the levels of alpha o or alpha s isoforms following NGF removal. These findings suggest that alpha o isoforms are involved in neuritic extension in PC12 cells.

Amino Acid Sequence↗
PubMed1995

Serotonin depletion by 5,7-dihydroxytryptamine does not affect G protein subunit levels in rat cortex.

To investigate the role of G proteins in denervation supersensitivity of the CNS serotonergic system, we examined the effect of lesioning serotonergic neurons on the abundance of cerebral cortical membrane G protein subunits in rats. Three weeks after intracisternal injection of 5,7-dihydroxytryptamine (5,7-DHT), which significantly reduced cortical 5-hydroxytryptamine (5-HT; -90%) and 5-hydroxyindoleacetic acid (approximately 98%) levels, no statistically significant differences were observed for G alpha s-1, G alpha s-s, G alpha i1, G alpha i2, G alpha q/11, G alpha 0, G beta 1 and G beta 2 immunoreactivity levels between sham-lesioned and 5,7-DHT lesioned rats. These data suggest that the functional supersensitivity of 5-HT neuronal system often observed following lesions of 5-HT fibers may not involve changes at the level of G proteins but may instead encompass other downstream elements of the 5-HT receptor signaling cascade.

Animals↗
PubMed1995

Effect of thyroid deficiency on Go alpha-subunit isoforms in developing rat cerebral cortex.

Postnatal development of G alpha o isoforms in rat cerebral cortex was studied by SDS-PAGE and immunoblotting. When rat cerebral cortical membranes were resolved on separating gels containing 9% acrylamide and 8 M urea, three electrophoretically distinct G alpha o-immunoreactive proteins were evident. Comparison of their electrophoretic mobilities and partial tryptic digest pattern with recombinant G alpha o1 or G alpha o1-specific antibody revealed that the slowest and intermediate-migrating bands represent unmodified and fatty acylated forms of G alpha o1 protein, respectively. The fastest-migrating band corresponds to G alpha o2. While the fatty acylated form of G alpha o1 is the predominant species, its appearance paralleled that observed for G alpha o2 in developing rat cortex. Perinatal hypothyroidism induced by methimazole treatment did not significantly alter the appearance of cerebral cortical G alpha o1 and G alpha o2 between days 1 and 22 postpartum. Our findings support the earlier idea that heterogeneity of G alpha o proteins in mammalian brain is likely the result of different co- or post-translational processings of each splice variant of G alpha o. While the appearance of G alpha o isoforms is developmentally regulated, they likely do not play an obligatory role in neonatal brain development. Alternatively, the expression of G alpha o isoforms in developing rat cortex may be controlled by an intrinsic signal(s) that is independent of the thyroid status.

Amino Acid Sequence↗
PubMed1994

Differential ontogenetic appearance and regulation of stimulatory G protein isoforms in rat cerebral cortex by thyroid hormone deficiency.

We have examined the effects of perinatal hypothyroidism on the levels of several G protein subunits in developing rat cerebral cortex. Thyroid deficiency significantly reduced the levels of the short form of G alpha s (G alpha s-s) by 70% and 83%, on P17 and P22, respectively, but had no effect on the long form of G alpha s (G alpha s-1), except that the G alpha s-1 levels were moderately increased on P22. Compared with age-matched controls, no significant differences were observed for G alpha i-1, G alpha i-2, G alpha o, G alpha q/11, G beta 1 and G beta 2 immunoreactivity in the cerebral cortex of the 22-day-old hypothyroid pups. These findings suggest that thyroid hormones may play an important role in controlling the pattern of expression of G alpha s isoforms during neonatal brain development and the reduced levels of G alpha s-s may contribute to some of the developmental abnormalities seen with perinatal hypothyroidism by altering signal transduction and intercellular communication.

Aging↗
PubMed1994

Reduced brain 5-HT and elevated NE turnover and metabolites in bipolar affective disorder.

Levels of norepinephrine (NE), serotonin (5-HT), dopamine (DA), and their major metabolites were determined in postmortem brain obtained from nine subjects with antemortem histories meeting DSM-III-R criteria for bipolar affective disorder. Compared with controls, no statistically significant differences were found in mean levels of NE, 5-HT, or DA in any brain area of bipolar subjects. NE turnover as estimated by the ratio of the major NE metabolite, 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG) to NE was increased in frontal (+107%), temporal (+103%), and occipital (+64%) cortex and thalamus (+83%). Significant decreases were found in the major 5-HT metabolite 5-hydroxyindoleacetic acid (5-HIAA), in frontal (-54%) and parietal cortex (-64%), and in 5-HIAA/5-HT ratio in temporal cortex (-55%), with a trend for decreases in both measures in caudate nucleus. In addition, levels of the major DA metabolite, homovanillic acid (HVA) were significantly decreased (-46%) in parietal cortex and HVA/DA ratios were significantly reduced (-66%) in occipital cortex obtained from bipolar compared to control subjects. Our data, taken together with previous findings regarding monoamines in postmortem brain of depressed and suicide subjects, suggest that decreased 5-HT metabolite levels and turnover may be common to all mood disorders. Increased cortical NE turnover, however, may be a more important component in the pathophysiology of bipolar disorder.

Adult↗
PubMed1994

Cerebral cortex beta-adrenoceptor binding in bipolar affective disorder.

Beta-Adrenoceptor density was measured in cerebral cortex membranes obtained postmortem from age-matched controls and subjects with bipolar disorder (BD). [125I]Iodopindolol (PIN) binding performed using a single point concentration was not different in frontal, occipital or temporal cortex in BD. Scatchard analysis of [125I]PIN binding in temporal cortex confirmed the lack of differences in binding density and no changes in KD between these two subject groups. These findings do not support alterations in the density or affinity of beta-adrenoceptor binding in cerebral cortex in BD.

Adrenergic beta-Antagonists↗
PubMed1994

Mononuclear leukocyte levels of G proteins in depressed patients with bipolar disorder or major depressive disorder.

Stimulatory (Gs) and inhibitory (G(i)) guanine nucleotide binding protein alpha subunit levels were measured in mononuclear leukocytes from 22 drug-free depressed patients (eight with bipolar disorder, 14 with major depressive disorder) and a comparison group of 17 age- and sex-matched healthy subjects. The levels of Gs alpha and G(i) alpha were significantly higher (160% and 114%, respectively) in the bipolar patients, but not the patients with major depressive disorder, than in the healthy subjects. These data add to the evidence for abnormalities in G protein levels and function in the pathophysiology of bipolar disorder.

Adult↗
PubMed1993

Effects of chronic lithium and carbamazepine treatment on G-protein subunit expression in rat cerebral cortex.

Although lithium and carbamazepine (CBZ) are effective in the treatment of bipolar affective disorder, their mechanism of action is still unknown. Recent evidence suggests that lithium and CBZ might exert their therapeutic effects by modulating the function of guanosine triphosphate (GTP)-regulatory (G) proteins associated with central nervous system second messenger systems. In the present study, we showed that chronic lithium administration decreases G alpha s, G alpha i1, and G alpha i2 messenger RNA (mRNA) abundance by 25%-30% in rat cerebral cortex. However, the levels of G alpha s, G alpha i1, and G alpha i2 mRNA were unaffected by chronic CBZ treatment. The effects of lithium on G alpha s, G alpha i1, and G alpha i2 mRNA levels appear to be selective, as the mRNA levels of G alpha o, G alpha x, G beta 1, G beta 2, and G beta 3 subunits remained unchanged. Two days after terminating chronic lithium treatment, changes in G alpha s, G alpha i1, and G alpha i2 mRNA levels were not demonstrable. Short-term administration of lithium (2 days), however, reduced only the G alpha i2 mRNA levels. Surprisingly, there was no significant difference in the amount of immunologically detectable G alpha s-s, G alpha s-1, G alpha i(1 + 2), G alpha 0, and G beta (1 + 2) in the cortex of rats chronically treated with lithium or CBZ, compared with controls.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1993

CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia.

Until recently, research on the neurochemical basis of affective disorders (AD) and schizophrenia (SCZ) focused on detecting postulated disturbances in presynaptic neurotransmitter release and metabolism, or postsynaptic receptor function. New insights into the molecular mechanisms involved in the propagation of neurotransmitter signals across biological membranes and in the regulation of neuronal responses have allowed the development of novel hypotheses, which may explain the altered postsynaptic neuroreceptor responsivity thought to be integral to the pathophysiology of these disorders. In this review we evaluate evidence from both basic science and clinical research implicating disturbances in postreceptor signal transduction in the pathophysiology and pharmacotherapy of AD and SCZ. Specific findings regarding potential postreceptor sites of pathophysiology are highlighted in each of these disorders, together with the growing body of data on the possible postreceptor loci of psychotropic drug action, especially lithium and antidepressants.

Animals↗